Exciting News!

We are thrilled about the market approval of Lecanemab in the EU, marking a promising breakthrough for millions affected by Alzheimer’s disease. Early detection is crucial, and in this field, our ASL team is at the forefront of research. Upcoming observational studies can be supported by our cutting-edge technology, which can non-invasively monitor the course of the disease.

Arterial Spin Labeling (ASL) represents a modern MRI technique for measuring regional brain perfusion and permeability by modifying the magnetization of blood water protons to serve as natural tracers. This method is entirely non-invasive, eliminating the need for ionizing radiation or external contrast agents.

The non-invasive nature of ASL provides numerous benefits for clinical research: it allows for repeated cerebral blood flow (CBF) measurements as often as needed and is suitable for use in vulnerable groups, such as patients with renal failure, elderly individuals or Alzheimer’s patients.